Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:GERNNYSE:RCUSNASDAQ:SYRENASDAQ:THRD On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeGERNGeron$1.59-2.2%$1.38$1.17▼$5.34$1.00B0.6911.50 million shs4.82 million shsRCUSArcus Biosciences$10.14+2.9%$8.45$6.50▼$18.98$1.07B0.83866,224 shs481,492 shsSYRESpyre Therapeutics$18.69+8.9%$14.27$10.91▼$40.26$1.12B2.72614,931 shs262,562 shsTHRDTF Financial$5.29$0.00$0.00▼$0.00$238.37M2.661.17 million shs157,907 shs7 AI Stocks to Invest in Today: Capitalizing on AI and Tech Trends in 2025Discover the top 7 AI stocks to invest in right now. This exclusive report highlights the companies leading the AI revolution and shaping the future of technology in 2025.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceGERNGeron+1.25%+13.29%+36.71%+1.25%-64.71%RCUSArcus Biosciences-1.35%+7.12%+19.08%-0.55%-36.39%SYRESpyre Therapeutics+1.12%+11.43%+21.70%-7.54%-49.03%THRDTF Financial0.00%+1.54%+2.72%+53.33%-62.77%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationGERNGeron3.0904 of 5 stars3.41.00.01.32.21.70.6RCUSArcus Biosciences2.7585 of 5 stars4.51.00.00.02.52.50.0SYRESpyre Therapeutics2.0691 of 5 stars3.61.00.00.01.42.50.6THRDTF Financial0.5734 of 5 stars1.04.00.00.00.01.70.6Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceGERNGeron 2.78Moderate Buy$5.06219.40% UpsideRCUSArcus Biosciences 2.90Moderate Buy$24.13138.04% UpsideSYRESpyre Therapeutics 3.25Buy$53.40185.65% UpsideTHRDTF Financial 2.00Hold$5.00-5.48% DownsideCurrent Analyst Ratings BreakdownLatest THRD, RCUS, SYRE, and GERN Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails5/9/2025RCUSArcus BiosciencesMorgan StanleySubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetOverweight ➝ Overweight$24.00 ➝ $22.005/8/2025GERNGeronScotiabankSubscribe to MarketBeat All Access for the recommendation accuracy ratingDowngradeSector Outperform ➝ Sector Perform$4.00 ➝ $1.505/8/2025RCUSArcus BiosciencesThe Goldman Sachs GroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetNeutral ➝ Neutral$15.00 ➝ $13.005/7/2025RCUSArcus BiosciencesWedbushSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingOutperform$33.005/7/2025RCUSArcus BiosciencesWells Fargo & CompanySubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetOverweight ➝ Overweight$29.00 ➝ $26.005/5/2025SYRESpyre TherapeuticsWedbushSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingOutperform$65.004/23/2025RCUSArcus BiosciencesBarclaysSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetOverweight ➝ Overweight$29.00 ➝ $14.004/8/2025SYRESpyre TherapeuticsLeerink PartnrsSubscribe to MarketBeat All Access for the recommendation accuracy ratingUpgradeStrong-Buy4/8/2025SYRESpyre TherapeuticsLeerink PartnersSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageOutperform$45.003/28/2025THRDTF FinancialStifel NicolausSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Hold$23.00 ➝ $5.003/18/2025SYRESpyre TherapeuticsWolfe ResearchSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageOutperform$27.00(Data available from 6/10/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookGERNGeron$116.29M8.68N/AN/A$0.46 per share3.45RCUSArcus Biosciences$141M7.61N/AN/A$6.17 per share1.64SYRESpyre Therapeutics$890K1,266.07N/AN/A($0.22) per share-84.97THRDTF FinancialN/AN/AN/AN/A$6.67 per shareN/ACompare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateGERNGeron-$184.13M-$0.21N/AN/AN/A-682.48%-67.53%-45.46%8/6/2025 (Estimated)RCUSArcus Biosciences-$307M-$4.19N/AN/AN/A-102.66%-45.59%-22.38%8/4/2025 (Estimated)SYRESpyre Therapeutics-$338.79M-$3.77N/AN/AN/AN/A-210.01%-44.40%8/6/2025 (Estimated)THRDTF Financial-$30.82M-$0.62N/AN/AN/AN/A-9.31%-9.03%N/ALatest THRD, RCUS, SYRE, and GERN EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/8/2025Q1 2025SYRESpyre Therapeutics-$0.76-$0.74+$0.02-$0.74N/AN/A5/8/2025Q1 2025THRDTF Financial-$0.26-$0.35-$0.09-$0.35N/AN/A5/7/2025Q1 2025GERNGeron-$0.04-$0.03+$0.01-$0.03$49.88 million$39.60 million5/6/2025Q1 2025RCUSArcus Biosciences-$1.02-$1.14-$0.12-$1.14$38.61 million$28.00 million3/27/2025Q4 2024THRDTF Financial-$0.38-$0.29+$0.09-$0.29N/AN/ACompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthGERNGeronN/AN/AN/AN/AN/ARCUSArcus BiosciencesN/AN/AN/AN/AN/ASYRESpyre TherapeuticsN/AN/AN/AN/AN/ATHRDTF FinancialN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioGERNGeron0.042.892.74RCUSArcus Biosciences0.085.245.24SYRESpyre TherapeuticsN/A7.327.32THRDTF FinancialN/A42.5042.50Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipGERNGeron73.71%RCUSArcus Biosciences92.89%SYRESpyre Therapeutics80.39%THRDTF Financial93.95%Insider OwnershipCompanyInsider OwnershipGERNGeron7.42%RCUSArcus Biosciences12.30%SYRESpyre Therapeutics15.43%THRDTF Financial5.90%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableGERNGeron70636.92 million585.76 millionOptionableRCUSArcus Biosciences500105.89 million80.26 millionOptionableSYRESpyre Therapeutics7360.28 million48.24 millionOptionableTHRDTF FinancialN/A45.06 million42.40 millionOptionableTHRD, RCUS, SYRE, and GERN HeadlinesRecent News About These CompaniesNortheast Dominates 2025 Highest Income Rankings, Study Says: See Where Your State StandsJune 9 at 1:23 PM | msn.comThird Harmonic Bio plans to liquidate the company, sell urticaria treatmentApril 14, 2025 | msn.comThird Harmonic Bio Announces Liquidation Plan: Stock Skyrockets 39% Pre-Market, But Retail’s ShatteredApril 14, 2025 | msn.comThird Harmonic Bio Announces Plan of Liquidation and DissolutionApril 14, 2025 | globenewswire.comThird Harmonic Bio Announces Fourth Quarter and Full Year 2024 Financial ResultsMarch 27, 2025 | globenewswire.comThird Harmonic Bio, Inc. (THRD) Loses -31.61% in 4 Weeks, Here's Why a Trend Reversal May be Around the CornerMarch 4, 2025 | zacks.comThird Harmonic Bio, Inc. (THRD) Upgraded to Buy: What Does It Mean for the Stock?February 14, 2025 | zacks.comDown -39.61% in 4 Weeks, Here's Why You Should You Buy the Dip in Third Harmonic Bio, Inc. (THRD)February 14, 2025 | zacks.comThird Harmonic Bio Announces Phase 1 Clinical Results for THB335 and Provides Corporate Strategic UpdateFebruary 11, 2025 | globenewswire.comThird Harmonic Bio to Participate in the 7th Annual Evercore HealthCONx ConferenceNovember 25, 2024 | globenewswire.comApple making foray into smart home IP camera market, says analyst Ming-Chi KuoNovember 14, 2024 | finance.yahoo.comUpdates to the British Virgin Islands Anti-Money Laundering regime and changes for MLROsNovember 12, 2024 | jdsupra.comWall Street Analysts Believe Third Harmonic Bio, Inc. (THRD) Could Rally 26.67%: Here's is How to TradeNovember 11, 2024 | zacks.com(LEAD) Netmarble swings to black in Q3 on steady-selling titlesNovember 8, 2024 | msn.comNissan plans 9,000 job cuts, slashes annual profit outlookNovember 7, 2024 | msn.comThird Harmonic Bio to Participate in Upcoming Investor Conferences in NovemberNovember 7, 2024 | globenewswire.comSarepta Therapeutics (SRPT) Q3 2024 Earnings Call TranscriptNovember 7, 2024 | msn.comInterest rates live updates: Bank of England base rate cut to help slash mortgage billsNovember 7, 2024 | msn.comThird Harmonic Bio Announces Third Quarter 2024 Financial ResultsNovember 7, 2024 | globenewswire.comMeet the Candidates: Q&A with candidates for the Ann Arbor School BoardNovember 5, 2024 | michigandaily.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeTHRD, RCUS, SYRE, and GERN Company DescriptionsGeron NASDAQ:GERN$1.58 -0.04 (-2.16%) As of 03:28 PM Eastern This is a fair market value price provided by Polygon.io. Learn more.Geron Corporation, a late-stage clinical biopharmaceutical company, focuses on the development and commercialization of therapeutics for myeloid hematologic malignancies. It develops imetelstat, a telomerase inhibitor that is in Phase 3 clinical trials, which inhibits the uncontrolled proliferation of malignant stem and progenitor cells in myeloid hematologic malignancies for the treatment of low or intermediate-1 risk myelodysplastic syndromes and intermediate-2 or high-risk myelofibrosis. The company was incorporated in 1990 and is headquartered in Foster City, California.Arcus Biosciences NYSE:RCUS$10.14 +0.29 (+2.89%) As of 03:28 PM Eastern This is a fair market value price provided by Polygon.io. Learn more.Arcus Biosciences, Inc., a clinical-stage biopharmaceutical company, develops and commercializes cancer therapies in the United States. The company's pipeline products include Domvanalimab, an anti-TIGIT antibody, which is in Phase 2 and Phase 3 clinical trial; and AB308, an investigational anti-TIGIT monoclonal antibody, which is in Phase 1b clinical trial to study people with advanced solid and hematologic malignancies. It also develops Etrumadenant, a dual A2a/A2b adenosine receptor antagonist, which is in Phase 2 clinical trial; Quemliclustat, a small-molecule CD73 inhibitor, which is Phase 1b and Phase 2 clinical trial; Zimberelimab, an anti-PD-1 antibody, which is in Phase 2 clinical trial for metastatic cell lung cancer and monotherapy; and AB521, an oral and small-molecule inhibitor of HIF-2a, which is in Phase 1 clinical trial for the treatment of Von Hippel-Lindau disease. In addition, the company's preclinical pipeline products include AB598, a CD39 antibody; and AB801, a small molecule Axl inhibitor. It has a clinical collaboration with AstraZeneca to evaluate domvanalimab in combination with durvalumab in a registrational phase 3 clinical trial in patients with unresectable Stage 3 NSCLC; and BVF Partners L.P. to support the discovery and development of compounds for the treatment of inflammatory diseases. Arcus Biosciences, Inc. was incorporated in 2015 and is headquartered in Hayward, California.Spyre Therapeutics NASDAQ:SYRE$18.69 +1.53 (+8.94%) As of 03:28 PM Eastern This is a fair market value price provided by Polygon.io. Learn more.Spyre Therapeutics, Inc., a preclinical stage biotechnology company, focuses on developing therapeutics for patients living with inflammatory bowel disease (IBD). It develops SPY001, a human monoclonal immunoglobulin G1 antibody designed to bind selectively to the a4ß7 integrin being developed for the treatment of IBD (ulcerative colitis and Crohn's disease). The company is also developing SPY002, a human monoclonal antibody (mAb)candidates designed to bind to tumor necrosis factor-like ligand 1A; and SPY120, a combination of SPY001 (anti-a4ß7) and SPY002 (anti-TL1A) antibodies, which are in preclinical studies. In addition, its other early-stage programs include SPY003, an anti-IL-23 mAb; SPY004, a novel mechanism of action (MOA) mAb; SPY130, a combination of anti-a4ß7 and anti-IL-23 mAbs; and SPY230, a combination of anti-TL1A and anti-IL-23 mAbs. The company was formerly known as Aeglea BioTherapeutics, Inc. and changed its name to Spyre Therapeutics, Inc. in November 2023. Spyre Therapeutics, Inc. was incorporated in 2013 and is based in Waltham, Massachusetts.TF Financial NASDAQ:THRDTF Financial Corporation is a savings and loan holding company. The Company's direct and indirect subsidiaries include Third Federal Bank (the Bank), Teragon Financial Corporation, Penns Trail Development Corporation and Third Delaware Corporation. The Bank is a community oriented Pennsylvania stock savings bank offering a variety of financial services to meet the needs of the communities it serves. As of December 31, 2011 the Bank operated fourteen branch offices in Bucks and Philadelphia Counties, Pennsylvania and in Mercer County, New Jersey. During the year ended December 31, 2011, the Company's subsidiary, TF Investments Corporation merged into TF Financial Corporation. In July 2013, the Company acquired Roebling Financial Corp, Inc. (Roebling) and its wholly-owned subsidiary, Roebling Bank. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Qualcomm: What Monday’s Jump Tells Us About the Stock's Prospects Meta Pulls Ahead of the Mag 7: Analysts Predict a Breakout Year ASML’s AI Edge: How Its EUV Tech Is Creating a New Monopoly Robinhood Drops on S&P Snub—Is a Bigger Pullback Coming? 3 Tightly-Held Growth Stocks Set Up for Short Squeezes Palantir Stock Holds Support, Despite Political Backlash Science Applications International Is a Wicked Hot Buy in June Why Unity Software May Be the AI Breakout No One Saw Coming Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
